Adding anlotinib in gradual or local progression on first-line EGFR-TKIs for advanced non-small cell lung cancer: A single-arm, multicenter, phase II trial

被引：0
|
作者：
Chen, H. [1 ]
Hu, Y. [2 ]
Fan, Y. [3 ]
Wu, G. [4 ]
Cang, S. [5 ]
Yang, Y. [6 ]
Yang, N. [7 ]
Ma, R. [8 ]
Jing, G. [9 ]
Liu, A. [10 ]
Xu, X. [11 ]
Tang, S. [12 ]
Cheng, Y. [13 ]
Yu, Y. [14 ]
Wu, Y-L. [1 ]
机构：
[1] Southern Med Univ, Guangdong Lung Canc Inst, Guangdong Prov Peoples Hosp,Guangdong Acad Med Sc, Guangdong Prov Key Lab Translat Med Lung Canc, Guangzhou, Peoples R China
[2] Hubei Canc Hosp, Dept Thorac Oncol, Wuhan, Peoples R China
[3] Univ Chinese Acad Sci, Canc Hosp, Dept Med Oncol, Zhejiang Canc Hosp, Hangzhou, Peoples R China
[4] Meizhou Peoples Hosp, Dept Oncol, Meizhou, Peoples R China
[5] Henan Prov Peoples Hosp, Dept Oncol, Zhengzhou, Henan, Peoples R China
[6] Third Peoples Hosp Chendu, Dept Thorac Surg, Chengdu, Peoples R China
[7] Cent South Univ, Hunan Canc Hosp, Affiliated Canc Hosp, Dept Thorac Med Oncol,Xiangya Sch Med, Changsha, Peoples R China
[8] Liaoning Canc Hosp, Med Oncol, Dept Thorac Canc, Shenyang, Peoples R China
[9] Inner Mongolia Autonomous Reg Peoples Hosp, Dept Oncol, Hohhot, Peoples R China
[10] Nanchang Univ, Dept Oncol, Affiliated Hosp 2, Nanchang, Peoples R China
[11] Wuhan Univ, Dept Oncol, Renmin Hosp, Hubei Gen Hosp, Wuhan, Peoples R China
[12] First Peoples Hosp Neijiang, Dept Oncol, Neijiang, Peoples R China
[13] Jilin Canc Hosp, Med Oncol, Changchun, Peoples R China
[14] Harbin Med Univ, Dept Internal Med, Canc Hosp, Harbin, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
22P
引用
收藏
页码：S53 / S53
页数：1
相关论文
共 50 条
  • [21] Sintilimab in combination with anlotinib in non-small cell lung cancer patients with uncommon EGFR mutations: A phase II, single-arm, prospective study
    Chen, K.
    Fan, Y.
    ANNALS OF ONCOLOGY, 2022, 33 : S39 - S39
  • [22] An updated network meta-analysis of EGFR-TKIs and combination therapy in the first-line treatment of the advanced EGFR mutation positive non-small cell lung cancer
    Qi, Y.
    Xia, X.
    Wei, S.
    Shao, L.
    Tian, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1045 - S1046
  • [23] An updated network meta-analysis of EGFR-TKIs and combination therapy in the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer
    Qi, Yuexiao
    Xia, Xiaojun
    Shao, Lihua
    Guo, Liyun
    Dong, Yumei
    Tian, Jinhui
    Xu, Lijun
    Niu, Ruijun
    Wei, Shihong
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [24] Docetaxel and Oxaliplatin as First-Line Therapy for Advanced Non-Small Cell Lung Cancer: A Phase II Trial
    Radhakrishnan, A.
    Bitran, J. D.
    Milton, D. T.
    Tolzien, K.
    Hallmeyer, S.
    Nabhan, C.
    JOURNAL OF CHEMOTHERAPY, 2009, 21 (04) : 439 - 444
  • [25] Phase II trial of satraplatin and paclitaxel in the first-line treatment of advanced non-small cell lung cancer
    Shipley, D.
    Spigel, D. R.
    Cavanaugh, C.
    Moore, Y.
    Hainsworth, J. D.
    Jones, S.
    Burris, H. A., III
    Sade, L.
    Yardley, D. A.
    Greco, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [26] Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer:: a phase II trial
    Laack, E
    Mende, T
    Benk, J
    Chemaissani, A
    Scholtze, J
    Lorenz, C
    Niestroy, A
    Dalhoff, K
    Müller, T
    Walter, T
    Dürk, H
    Edler, L
    Hossfeld, DK
    EUROPEAN JOURNAL OF CANCER, 2001, 37 (05) : 583 - 590
  • [27] Microwave ablation as local consolidative therapy for patients with extracranial oligometastatic EGFR-mutant non-small cell lung cancer without progression after first-line EGFR-TKIs treatment
    Ni, Yang
    Ye, Xin
    Yang, Xia
    Huang, Guanghui
    Li, Wenhong
    Wang, Jiao
    Han, Xiaoying
    Wei, Zhigang
    Meng, Min
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (01) : 197 - 203
  • [28] Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study
    Li, Meng-Xia
    He, Hao
    Ruan, Zhi-Hua
    Zhu, Yu-Xi
    Li, Rong-Qing
    He, Xiao
    Lan, Bao-Hua
    Zhang, Zhi-Min
    Liu, Guo-Dong
    Xiao, Hua-Liang
    Wu, Yan
    Zhu, Bo
    Wang, Ge
    Yang, Zhen-Zhou
    BMC CANCER, 2017, 17
  • [29] Microwave ablation as local consolidative therapy for patients with extracranial oligometastatic EGFR-mutant non-small cell lung cancer without progression after first-line EGFR-TKIs treatment
    Yang Ni
    Xin Ye
    Xia Yang
    Guanghui Huang
    Wenhong Li
    Jiao Wang
    Xiaoying Han
    Zhigang Wei
    Min Meng
    Journal of Cancer Research and Clinical Oncology, 2020, 146 : 197 - 203
  • [30] Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs
    Brueckl, Wolfgang
    Tufman, Amanda
    Huber, Rudolf Maria
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (02) : 143 - 155
12345